THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

(Please scan this QR code to view the Prospectus)

NEOCHEM
Enabling Growth

NEOCHEM BIO SOLUTIONS LIMITED

(FORMERLY KNOWN AS NEOCHEM BIO SOLUTIONS PRIVATE LIMITED AND NEOCHEM TECHNOLOGIES PRIVATE LIMITED)

CORPORATE IDENTIFICATION NUMBER: U24304GJ2017PLC097754

Our Company was originally formed as a partnership firm under the Indian Partnership Act, 1932 ("**Partnership Act**") in the name and style of "M/s Vinayak Dyes & Chemical Industries", pursuant to Deed of Partnership dated March 6, 1978. Vinayak Dyes & Chemical Industries was changed to "Neochem Technologies" with effect from January 6, 2006 and further the firm was converted from Partnership Firm to Private Limited company under Part I chapter XXI of the Companies Act, 2013 and received a Certificate of Incorporation from the Registrar of Companies, Ahmedabad at Gujarat ("**RoC**") on June 6, 2017 as "Neochem Technologies Private Limited". Furthermore, the name of our Company was changed from Neochem Technologies Private Limited to Neochem Bio Solutions Private Limited and Certificate of Name change dated March 18, 2025 was received by the Company. Subsequently, our Company was converted into a public limited company pursuant to a special resolution passed by our shareholders resolution dated March 26, 2025, and the name of our Company was changed to "Neochem Bio Solutions Limited". A fresh certificate of Incorporation consequent upon conversion from a Private Limited company to Public Limited company dated April 15, 2025 was issued by the Registrar of Companies, Central Processing Centre. For details of the change in the registered office of our Company, see *"History and Certain Corporate Matters"* on page 213 of the Prospectus.

Registered Office: 303, W1, Opp. Vikramnagar Colony, Off. Iscon - Ambli Road, Ambli, Ahmedabad - 380058, Daskroi, Gujarat, India.

Website: www.neochem.in; **E-Mail:** compliance@neochem.in; **Telephone No.:** +91 -079- 35217792; **Contact Persons:** Shradha Sarthak Agrawal - Company Secretary and Compliance Officer /– Pradip Ramniklal Solanki – Chief Financial Officer

PROMOTERS OF OUR COMPANY: SWAPNIL RAMESHBHAI MAKATI AND HEMANGINI SWAPNIL DATHIA

PROPOSED LISTING

Our Company has filed the Prospectus dated December 4, 2025, with the RoC ("**the Prospectus**") and the Equity Shares (as defined below) are proposed to be listed on the EMERGE Platform of National Stock Exchange of India Limited ("**NSE**" or "**NSE EMERGE**"). Our Company has received in–principle approval letter dated October 23, 2025 from NSE for listing our Equity Shares and also for using its name in the Prospectus for listing of our Equity Shares on NSE. It is distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Issue Document has been cleared or approved by NSE nor does it clearly the correctness or completeness of any of the contents of the Issue Document. The Investors are advised to refer to the Prospectus for the full text of the *"Disclaimer Clause of NSE"* on page 323 of the Prospectus.

The Equity Shares are Proposed to be listed on NSE EMERGE and the listing and trading of the Equity Shares are expected to commence on December 9, 2025 (Subject to receipt of listing and trading approval from NSE).

BRIEF DESCRIPTION OF THE BUSINESS OF THE ISSUER COMPANY

We are a specialty performance chemical company engaged in the business of manufacturing specialty performance chemicals with a diverse portfolio customized formulations across four primary product segments viz. (i) Polymers, (ii) Surfactants, (iii) Silicones, and (iv) Esters & biobased sustainable solutions. Our products are essential and used in industries such as textile & garment washing, home & personal care (HPC), institutional and industrial cleaners, water treatment, paints and coatings, paper and pulp, construction, rubber and dyes and pigments. Our Company is accredited with recognized process certifications such as ISO 9001:2015, ISO 14001 and ISO 45001. Our product certifications include ZDHC Level 3 and GOTS 7.0.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF UPTO 45,88,800 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH OF NEOCHEM BIO SOLUTIONS LIMITED (FORMERLY KNOWN AS NEOCHEM BIO SOLUTIONS PRIVATE LIMITED & NEOCHEM TECHNOLOGIES PRIVATE LIMITED), ("NEOCHEM" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹98/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹88/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹4,497.02 LAKHS ("THE ISSUE"), OF WHICH 2,32,800 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹98/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹88/- PER EQUITY SHARE AGGREGATING TO ₹228.14 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 43,56,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹98/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹88/- PER EQUITY SHARE AGGREGATING TO ₹4,268.88 LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.80% AND 25.44%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS AS AMENDED READ WITH RULE 19(2)(B) OF SECURITIES CONTRACT (REGULATION) RULES, 1957, AS AMENDED. (IPO OF SMALL AND MEDIUM ENTERPRISES).

For further details, please refer to chapter titled *"Term of the Issue"* on Page 329 of the Prospectus.

PRICE BAND: ₹93 TO ₹98 PER EQUITY SHARE OF FACE VALUE ₹10 EACH
ISSUE PRICE: ₹98 PER EQUITY SHARE OF FACE VALUE ₹10 EACH.
ANCHOR INVESTOR ISSUE PRICE: ₹98 PER EQUITY SHARE. | THE ISSUE PRICE IS 9.80 TIMES OF THE FACE VALUE

BID/ ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING OPENED AND CLOSED ON	**MONDAY, DECEMBER 1, 2025**
BID/ISSUE OPENED ON	**TUESDAY, DECEMBER 2, 2025**
BID/ISSUE CLOSED ON	**THURSDAY, DECEMBER 4, 2025**
PROPOSED LISTING	**TUESDAY, DECEMBER 9, 2025***

Subject to receipt of listing and trading approval from NSE Emerge.

RISK TO INVESTORS

For details refer to section titled *"Risk Factors"* on page 32 of the Prospectus

1. We derive a substantial portion of our revenue from the textile industry. Consequently, any material decline in the performance of the textile sector, or our failure to sustain, grow, or efficiently manage our sales within this sector, may materially and adversely affect our business operations, financial condition and results of operations.
2. Our Company derives revenue from diversified customers. Our inability to acquire new customers or loss of all or a substantial portion of any of our major customers, for any reason and/or continued reduction of the business from them, could have a material adverse impact on our business, results of operations, cash flows and financial condition.
3. We do not maintain long-term contractual arrangements with the majority of our customers. As a result, the loss of one or more key customers, or any significant reduction in their demand for our products, could materially and adversely affect our business operations, financial condition, results of operations and cash flows.
4. Underutilization of the installed capacities at our Company may have an adverse impact on our growth and future profitability.
5. We derive a significant portion of our revenue from operations from domestic sales which exposes us to risks specific to Indian geographies and market.
6. We are required to adhere to quality standards in the manufacturing of our products. Our inability to comply with such parameters may result in termination or loss of business from our customers which, in turn, may have a material adverse effect on our business prospects and results of operations.
7. A significant increase in the cost of raw materials, particularly if not matched by a corresponding increase in product pricing or revenue, could materially and adversely affect our profit margins and overall financial performance. If we are unable to pass on these increased costs to our customers, it may result in reduced profitability and negatively impact our results of operations and financial condition.
8. We have not made any long-term supply arrangement or agreement with our suppliers. In an eventuality where our suppliers are unable to deliver us the required materials, at a competitive price, in a time-bound manner it may have a material adverse effect on our business operations and profitability.
9. Our manufacturing facility situated in Moraiya, Ahmedabad is critical for our business and any disturbance, slowdown or shutdown of our Moraiya manufacturing facility, may have an adverse impact on our business, results of operations and financial conditions
10. Our operations can be adversely affected in case of industrial accidents at our manufacturing units. Further, any fire or mishap or accidents of such nature at the Company's facilities could lead to accident claims and damage and loss of property, inventory, raw materials, etc.
11. The Price/ Earnings ratio based on basic and diluted EPS for Fiscal 2025 for the company at the Cap price is 14.76.
12. Weighted Average Return on Net worth for the Fiscals 2025, 2024 and 2023 is 33.41%.
13. Weighted Average cost of acquisition, Floor and Cap Price

Period	Weighted Average Cost of Acquisition (in ₹)^	Cap Price is 'X' times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price (in ₹)
Last one year	Nil	Nil	Nil
Last eighteen months	5.71	17.16	Nil – 5.71#
Last three years	7.87	12.45	Nil – 7.87#

^As certified by M/s Patel Mehta & Associates, Chartered Accountants, by way of their certificate dated November 24, 2025.

#After giving effect to the bonus Equity Shares in the ratio of 3:4 on July 5, 2025

1. **Average Cost of Acquisition of Equity Shares by our Promoters**

Sr. No.	Name of Promoter	No. of Equity Shares held	Average cost of acquisition per Equity Share (in ₹)
1.	Swapnil Rameshbhai Makati	93,41,675	6.00
2.	Hemangini Swapnil Dathia	10,80,625	2.52

#As certified by M/s Patel Mehta & Associates, Chartered Accountants, pursuant to their certificate dated December 4, 2025

This Issue was made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("**SCRR**") read with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50 % of the Net Issue was available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**", the "**QIB Portion**"), provided that our Company, in consultation with the Book Running Lead Manager, allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("**Anchor Investor Portion**"), of which 33.33% shall be reserved for domestic mutual funds and 6.67% shall be reserved for life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds and life insurance companies and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares was added to the Net QIB Portion. Further, 5% of the Net QIB Portion was available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion was available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, the aggregate demand from Mutual Funds was less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion was added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue was available for allocation on a proportionate basis to Non-Institutional Investors wherein (a) one third of the portion available to Non-Institutional Investors was reserved for Applicants with Application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs; (b) two third of the portion available to Non-Institutional Investors was reserved for Applicants with Application size of more than ₹10 lakhs; and (c) any unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), was allocated to Applicants in the other sub-category of Non-Institutional Investors; and not less than 35% of the Net Issue was available for allocation to Individual Investors, who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) were required to mandatorily utilize the Application Supported by Blocked Amount ("**ASBA**") process providing details of their respective ASBA accounts, in which the corresponding Bid Amounts was blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors were not permitted to participate in the Issue through the ASBA process. For details, see ***"Issue Procedure"*** on page 343 of the Prospectus.

SUBSCRIPTION DETAILS

The bidding for Anchor investors opened and closed on Monday, December 1, 2025. The company received 07 Anchor Investors application for 17,42,400 Equity Shares. The Anchor Investor Allocation Price was finalized at ₹98 per Equity Share. Such 07 Anchor Investors through 07 Anchor Investor Application Forms were allocated 13,03,200 Equity Shares at a price of ₹98 per Equity Share under the Anchor Investor Portion, aggregating to ₹12,77,13,600.

The issue (excluding Anchor Investor Portion) received applications for 4,77,40,800 Equity Shares (before rejections and after invalid bids Multiple/Duplicate) resulting in 14.53 times subscription (including reserved portion of market maker). The Details of the Applications received from various categories (before rejection) are as under:

The details of the Applications Received (Before rejections):

Category	No. of Applications	No. of Shares	Reserved	No. of Times Subscriptions	Amount
Market Maker	1	2,32,800	2,32,800	1.00	2,28,14,400.00
QIB	27	1,91,42,400	8,71,200	21.97	1,87,59,55,200.00
NII (Upto 10 Lakhs)	668	26,08,800	2,18,400	11.95	25,55,94,000.00
NII (More than 10 Lakhs)	967	1,13,47,200	4,36,800	25.98	1,11,09,15,600.00
Individual Investor	6,004	1,44,09,600	15,26,400	9.44	1,41,20,01,600.00
TOTAL	**7,667**	**4,77,40,800**	**32,85,600**	**14.53**	**4,67,72,80,800.00**

Final Demand

A summary of the final demand as per NSE as on the Bid/Issue Closing Date at different Bid Prices is as under:

Sr. No	Bid Price	Bids Quantity	% of Total	Cumulative Total	% Cumulative Total
1	93	3,21,600	0.59	3,21,600	0.59
2	94	12,000	0.02	3,33,600	0.61
3	95	39,600	0.07	3,73,200	0.68
4	96	18,000	0.03	3,91,200	0.71
5	97	24,000	0.04	4,15,200	0.76
6	98	5,45,28,000	99.24	5,49,43,200	100.00
	TOTAL	**5,49,43,200**	**100.00**		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange – NSE on Friday, December 5, 2025.

1) **Allocation to Individual Investors (After Rejections):** The Basis of Allotment to the Individual Investors, who have bid at or above the Issue Price of ₹98 per equity shares, was finalized in consultation with NSE. The category was subscribed by 9.36 times i.e. for 1,42,82,400 Equity Shares. Total number of shares allotted in this category is 15,26,400 Equity Shares to 636 successful applicants. The category wise details of the Basis of Allotment are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	2400	5,951	100.00	1,42,82,400	100.00	2400	11:103	15,26,400
	TOTAL	**5,951**	**100.00**	**1,42,82,400**	**100.00**			**15,26,400**

2) **Allocation to Non-Institutional Investors – More than 2 Lots & Less than ₹10,00,000/- (After Rejections):** The Basis of Allotment to Non-Institutional Investors (more than 2 Lots and up to ₹10,00,000/-), who have bid at Issue Price of ₹98 per equity shares, was finalized in consultation with NSE. The category was subscribed by 11.81 times i.e. for 25,78,800 Equity Shares. Total number of shares allotted in this category is 2,18,400 Equity Shares to 60 successful applicants. The category wise details of the Basis of Allotment of the said category (on sample basis) are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	3,600	588	88.96	21,16,800	82.08	3,600	54:588	1,94,400
2	4,800	33	4.99	1,58,400	6.14	3,600	3:33	10,800
3	6,000	14	2.12	84,000	3.26	3,600	1:14	3,600
4	7,200	10	1.51	72,000	2.79	3,600	1:10	3,600
5	8,400	5	0.76	42,000	1.63	3,600	0:5	0
6	9,600	11	1.66	1,05,600	4.09	3,600	1:11	3,600
7	0	All allottees from Serial no 02 to 06 for 1 (one) lot of 1200 shares				1,200	2:6	2,400
	TOTAL	**661**	**100.00**	**25,78,800**	**100.00**			**2,18,400**

3) **Allocation to Non-Institutional Investors – More than ₹10,00,000/- (After Rejections):** The Basis of Allotment to the Non-Institutional Investors (more than ₹10,00,000/-), who have bid at Issue Price of ₹98 per equity shares, was finalized in consultation with NSE. The category was subscribed by 25.27 times i.e. for 1,10,38,800 Equity Shares. Total number of shares allotted in this category is 4,36,800 Equity Shares to 121 successful applicants. The category wise details of the Basis of Allotment for the said category (on sample basis) are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	10,800	929	96.77	1,00,33,200	90.89	3,600	117:929	4,21,200
2	12,000	10	1.04	1,20,000	1.09	3,600	1:10	3,600
3	13,200	8	0.83	1,05,600	0.96	3,600	1:8	3,600
4	19,200	6	0.63	1,15,200	1.04	3,600	1:6	3,600
5	18,000	2	0.21	36,000	0.33	3,600	0:2	0
6	43,200	1	0.10	43,200	0.39	3,600	0:1	0
7	57,600	1	0.10	57,600	0.52	3,600	0:1	0
8	60,000	2	0.21	1,20,000	1.09	3,600	0:2	0
9	4,08,000	1	0.10	4,08,000	3.70	3,600	0:1	0
10	0	All applicants from Serial no 05 to 09 for 1 (one) lot of 3600 shares				3,600	1:7	3,600
11	0	All allottees from Serial no 01 to 10 for 1 (one) lot of 1200 shares				1,200	1:121	1,200
	TOTAL	**960**	**100.00**	**1,10,38,800**	**100.00**			**4,36,800**

4) **Allocation to QIBs excluding Anchor Investors (After Rejections):** The Basis of Allotment to QIBs, who have bid at Issue Price of ₹98 per equity shares, was finalized in consultation with NSE. The category was subscribed by 21.97 times i.e. for 1,91,42,400 Equity Shares. Total number of shares allotted in this category is 8,71,200 Equity Shares to 27 successful applicants. The category wise details of the Basis of Allotment are as under:

CATEGORY	FI'S/BANK'S	MF'S	IC'S	NBFC'S	AIF	FPC	VC'S	Total
ALLOTMENT	-	-	-	2,78,400	2,29,200	3,40,800	22,800	**8,71,200**

5) **Allocation to Anchor Investors (After Rejections & Withdrawal):** The Company in consultation with the BRLM has allotted 13,03,200 Equity Shares to 07 Anchor Investors at Anchor Investor Issue Price of ₹98 per equity shares in accordance with the SEBI ICDR Regulations. The category wise details of the Basis of Allotment are as under:

CATEGORY	FI'S/BANK'S	MF'S	IC'S	NBFC'S	AIF	FPC	Others	Total
ALLOTMENT	-	-	-	-	13,03,200	-	-	**13,03,200**

6) **Allocation to Market Maker (After Rejections):** The Basis of Allotment to Market Maker, who have bid at Issue Price of ₹98 per equity shares or above, was finalized in consultation with NSE. The category was subscribed by 1 time i.e. for 2,32,800 shares the total number of shares allotted in this category is 2,32,800 Equity Shares. The category wise details of the Basis of Allotment are as under:

No. of Equity Shares Applied For (Category wise)	No. of Application Received	% to total	Total No. of Equity Shares applied in this category	% to total	No of equity shares Allocation per Applicant	Ratio	Total No. of shares allocated/ allotted
2,32,800	1	100.00	2,32,800	100.00	2,32,800	1:1	2,32,800

The Board of Directors of the Company at its meeting held on Friday, December 5, 2025 has approved the Basis of Allocation of Equity Shares as approved by the Designated Stock Exchange viz. NSE and has authorized the corporate action for issue of the Equity Shares to various successful applicants. The CAN-cum-allotment advices and/or notices have been forwarded to the email ids and address of the Applicants as registered with the depositories / as filled in the application form on Friday, December 5, 2025. Further, the instructions to Self Certified Syndicate Banks for unblocking the amount has processed on Saturday, December 06, 2025. In case the same is not received within ten days, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on the NSE within three working days from the date of the closure of the issue.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated December 4, 2025.

DISCLOSURE PERTAINING TO THE BRLM'S TRACK RECORD ON PAST ISSUES WITH BREAKUP OF HANDLINGS OF SME AND MAIN BOARD IPOS FOR CURRENT YEAR AND FOR LAST THREE YEARS.

VIVRO FINANCIAL SERVICES PRIVATE LIMITED

TYPE	FY 2023-24	FY 2024-25	FY 2025-26
SME IPO	**1**	**4**	**4**
MAIN BOARD IPO	**-**	**-**	**-**

INVESTORS PLEASE NOTE

The details of the allotment made will also be hosted on the website of the Registrar to the issue, MUFG Intime India Private Limited at www.in.mpms.mufg.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole applicants, serial number of the Bid cum Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
VIVRO	MUFG MUFG Intime
Vivro Financial Services Private Limited Vivro House, 11 Shashi Colony, Opp Suvidha Shopping Center, Paldi, Ahmedabad – 380007 Gujarat, India. **Telephone:** +91-79-4040 4242; **E-mail Id:** investors@vivro.net **Investor Grievance Id:** investors@vivro.net **Website:** www.vivro.net; **Contact Person:** Kruti Saraiya/Jay Dodiya **SEBI Registration No.:** INM000010122 **CIN:** U67120GJ1996PTC029182	**MUFG Intime India Private Limited** ***(Formerly Link Intime India Private Limited)*** C-101, Embassy 247 , L B S Marg, Vikhroli (West), Mumbai 400083, (Maharashtra), India. **Telephone:** +91 810 811 4949; **Website:** www.in.mpms.mufg.com **Email ID:** neochem.smeipo@in.mpms.mufg.com **Investor Grievance:** neochem.smeipo@in.mpms.mufg.com **Contact Person:** Shanti Gopalkrishnan; **SEBI Registration No.:** INR000004058 **CIN:** U67190MH1999PTC118368

Neochem Bio Solutions Limited
Sd/-
Swapnil Rameshbhai Makati
Managing Director
DIN: 00188382

Date : December 8, 2025
Place : Ahmedabad

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF NEOCHEM BIO SOLUTIONS LIMITED.

Disclaimer: Neochem Bio Solutions Limited has filed a Prospectus dated December 4, 2025 with the ROC. The Prospectus is available on the website of the SEBI at www.sebi.gov.in as well as on the website of the BRLM i.e., Vivro Financial Services Private Limited at www.vivro.net, the website of the NSE at www.nseindia.com. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, see *"Risk Factors"* on page 32 of the Prospectus. The Equity Shares issued in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "Qualified Institutional Buyers" (as defined in Rule 144A of the Securities Act) under Section 4(a) of the Securities Act and (ii) outside the United States in offshore transaction in reliance on Regulation S under the Securities Act and the applicable laws of the jurisdiction where those offer and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

KIRIN ADVISORS

Size: 32.9x50cm